Covid vaccine booster shots for Delta variant are being exaggerated by drug companies

[ad_1]

This summer should have been different. Flushed with the world’s best Covid-19 vaccines, America could have vaccinated its way out of the pandemic. But as a highly virulent delta variant has spread in a half-immunized country, infections have soared, mask guidelines have been duly revised, and, most worryingly, calls for boosting the vaccine are gaining db as a breakthrough infection (Covid infection in a fully vaccinated person) is rising.

Science rather than the greed of pharmaceutical executives should be our driving force in matters of vaccines and public health.

The issue of boosters is likely to gain more prominence after the Centers for Disease Control and Prevention warned Friday that new data on the delta variant shows how the war against the coronavirus has “changed.” While the CDC’s description of a strain more contagious and potentially more severe than its predecessors was completely unexpected, the astonishing susceptibility to superinfection for which the delta variant is responsible will spark debates about whether the booster shots could stop it And again the impenetrable immunity of the vaccinated people is restored.

Even before the results of the Centers for Disease Control and Prevention were announced, the issue of additional injections was already gaining momentum after data from Israel, where the Delta is also the dominant strain, recently showed that its vaccinated population is increasingly vulnerable to sudden infections. The Department of Health found that a dose of Pfizer was only 39 percent effective in preventing symptomatic Covid infections from late June to mid-July, a drop from levels seen this winter and early spring. Although the study was small and covered a tight period of time, the state announced Thursday that it will begin providing a booster dose to Israelis over 60 who were vaccinated more than five months ago.

Related

The decision echoed concerns amplified by Pfizer and fellow vaccine maker Moderna that vaccine efficacy would decline over time and their promotion of boosters as a way to raise the body’s declining immunity. Armed with new data on Wednesday, Pfizer claimed that the third shot would powerfully enhance protection via antibodies — proteins circulating in the blood that bind to and neutralize the virus — against the superinfectious delta variant.

But the statements of pharmaceutical companies contradict the facts of medical science and insult the development of the immune system in the body. After creating fantastic vaccines whose efficacy has exceeded even the most optimistic expectations, it appears that Pfizer is trying to create a new multibillion-dollar need for boosters that clearly do not exist outside the elderly or immunocompromised.

For now, the injections already given prime the immune systems to defeat Covid and achieve their goal of avoiding hospitalization and death. While this is welcome news for the health of the vaccinated population, it is disturbing for the drug companies’ bottom line: after all, the more doses a person requires, the more money they get.

As Covid wiped out America’s hospitals and became the third leading cause of death in 2020, Pfizer and Moderna were among those who responded with powerful vaccines that not only made the worst Covid outcomes extremely rare, but also dramatically reduced the likelihood of minor infection and inflammation. The development of symptoms. While this scientific achievement has been welcomed and praised, the remarkable efficacy has also created unrealistic expectations of what a vaccine can and aims to achieve.

Related

“The promise of all vaccines is against severe disease, hospitalization and death,” said Monica Gandy, MD, professor of medicine at the University of California, San Francisco. She noted that “there has never been a promise to sterilize immunity,” which means the complete absence of infection and symptoms. “This is the disappointment that is happening to the public at the moment.”

The critical finding is that even against the most formidable delta variant, the Pfizer vaccine continues to provide protection against the worst outcomes. In a British study published last week in the New England Journal of Medicine on the effectiveness of two doses of Pfizer against the delta variant, the vaccine was found to be 88% effective in preventing symptomatic disease, and although it was not published in the results, it is assumed that higher in Prevention of severe diseases.

Although there are limitations to the Israeli numbers, they also found that the Pfizer vaccine is more than 90 percent successful against serious diseases. Additionally, a study published in the New England Journal of Medicine on Wednesday found that sudden infections in Israeli health care workers were mostly mild or asymptomatic.

These numbers should provide reassurance as we hear about a surge in still rare infections (2.6 percent in Israeli health care workers described in the study published Wednesday), which will occur as the vaccination pool expands amid ubiquitous and sensitive PCR testing, mitigating . Public health measures and the infectious delta variant. Even a small percentage of cases in the United States’ 165 million people who have been fully vaccinated would look like a lot of people. But despite this rise, unvaccinated people are responsible for almost all hospitalizations and deaths in the country during the pandemic phase when the delta variant completely ascends.

Related

None of this, however, prevented the daily increase in alarming reports and selective studies that vaccinated immunity weakens as vaccination-induced circulating antibodies decreases over time. Although antibody tests are readily available, easy to measure, and provide instant gratification, their evaluation is not entirely illuminating at this point. Although it has historically been a critical yardstick for evaluating other types of vaccines, we still lack the full knowledge of how well it reports the efficacy of the revolutionary mRNA mechanism used by Pfizer and Moderna vaccines.

We know that the antibody response from these vaccines is diminished, but we do not know what the protection threshold is. “We don’t have enough information about mRNA vaccines,” said Mark Slivka, a vaccinologist at Oregon Health & Science University. “All other vaccine-preventable diseases are prevented by antibodies, which is why people are so focused on that.”

It is often forgotten that these antibodies represent just one layer of the complex designed to thwart Covid’s attack on the body. Even as these antibodies disappear in the months following vaccination, the adaptive immune system trained by the Covid vaccine remains intact and ready to pounce in a matter of days or less if the virus is detected in the body.

This long-term immunity is supported by two types of cells that function after penetration of the initial wall of antibodies. While the persistent virus may cause symptoms at this point, this other arm of the immune system will work to stop the further progression of Covid and prevent serious illness.

One of them, memory B cells, produces many additional antibodies. Other T cells target and destroy virus-infected cells independently of antibodies. mRNA vaccines stimulate the “vigorous” and sustained production of memory B cells after the vaccine is administered. Memory B cells charged with the vaccine can recognize various Covid variants. Finally, vaccine-induced T cells not only protect against severe disease but also remain robust against variants.

The critical finding is that even against the most formidable delta variant, the Pfizer vaccine continues to provide protection against the worst outcomes.

“Memory B cells are a wonderful fallback response to anything bypassing antibodies like these escape-disrupting variants,” Slifka said. “That’s the beautiful thing about these backup mechanisms: They hit the target from multiple angles.”

This does not mean that there will be no eligible weapons that need the booster Covid vaccinations. Over time, groups such as immunocompromised people and the elderly, whose responses to vaccines are weak or not strong, are likely to benefit from these additional shots to maintain their defenses. But as we advance in a world where Covid becomes a part of our daily lives, science, not the greed of pharmaceutical CEOs, must be our driving force in matters of vaccines and public health.

“Corporate CEOs are the main messengers of reinforcers, not scientists. Those who seek profit take the message,” Gandhi emphasized. “We need to clear ourselves of conflicts of interest before we discuss this problem.”

Dr. Jalal Beg is a physician and writer based in Chicago. His work has appeared in The Washington Post, The Atlantic, Foreign Policy, The Guardian, Elvis, Slate, Religion News Service and others.

[ad_2]